Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1701610

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Prices
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what progress they have made with the proposed amendments to the Part IX of the Drug Tariff, including any impact assessments on the future provision of medical technologies in the UK; how these proposals meet the ambitions of the Life Sciences Vision; and what steps they are taking to ensure that there is sufficient patient choice following the outcome of the consultation.
	tabling member printed	Baroness Finlay of Llandaff
	uin	HL3841
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The consultation response on the proposed amendments to Part IX and the final impact assessment is expected to be released in May 2024, and will outline the Government’s response.</p><p>The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on intend to increase meaningful choice, not to decrease choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers.</p><p>These proposals support the Life Sciences Vision, and are designed to increase innovation and alignment between partners in the health and care system. The enhanced assessment process will allow comparison between products based on their merits, increasing transparency and competition, and encouraging new products and small and medium sized businesses to enter the market. The proposed introduction of environmental attributes in social value scoring increases the vision to help the National Health Service meet Net Zero.</p><p>The Department is aware that there are some very good devices in use, relied upon by clinicians and patients. Part IX will remain a list of devices available to be prescribed in the community via the FP10 prescription route. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and NHS organisations. The Department will share a timeline of proposed changes taken forward, in due course.</p> answering member printed Lord Markham grouped question UIN HL3842 question first answered 22/04/2024 15:04:52 answering member 4948 label Biography information for Lord Markham
	tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1701611

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Prices
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government how they plan to formally engage with the wider health sector and industry partners on the next stages in the development of proposed changes to Part IX of the Drug Tariff, following the conclusion of the consultation on these proposals.
	tabling member printed	Baroness Finlay of Llandaff
	uin	HL3842
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The consultation response on the proposed amendments to Part IX and the final impact assessment is expected to be released in May 2024, and will outline the Government’s response.</p><p>The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on intend to increase meaningful choice, not to decrease choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers.</p><p>These proposals support the Life Sciences Vision, and are designed to increase innovation and alignment between partners in the health and care system. The enhanced assessment process will allow comparison between products based on their merits, increasing transparency and competition, and encouraging new products and small and medium sized businesses to enter the market. The proposed introduction of environmental attributes in social value scoring increases the vision to help the National Health Service meet Net Zero.</p><p>The Department is aware that there are some very good devices in use, relied upon by clinicians and patients. Part IX will remain a list of devices available to be prescribed in the community via the FP10 prescription route. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and NHS organisations. The Department will share a timeline of proposed changes taken forward, in due course.</p> answering member printed Lord Markham grouped question UIN HL3841 question first answered 22/04/2024 15:04:52 answering member 4948 label Biography information for Lord Markham
	tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1701641

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Professions: Mental Health
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what assessment they have made of the impact on the mental health of medical practitioners of withdrawing NHS Practitioner Health services for new applicants.
	tabling member printed	Lord Turnberg
	uin	HL3872
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>We recognise that the NHS Practitioner Health service is valued by many doctors. NHS England is reviewing the service as part of a wider review of its mental health and wellbeing offer to National Health Service staff. It was confirmed on 15 April 2024 that the service will continue to accept new patients from primary and secondary care whilst this review is undertaken over the next 12 months. NHS England will confirm future arrangements once the review has been completed.</p> answering member printed Lord Markham question first answered 22/04/2024 14:47:45 answering member 4948 label Biography information for Lord Markham
	tabling member	2537 label Biography information for Lord Turnberg

1700671

	registered interest
	date	15/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Shortages
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what steps they are taking to mitigate the current shortage of the psychotropic medication Olanzapine, Risperidone and Haloperidol following the sudden departure of two generic manufacturers from the UK market.
	tabling member printed	Lord Carlile of Berriew
	uin	HL3729
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>We are aware that there have been supply constraints with olanzapine 210 milligram, 300 milligram, and 405 milligram powder and solvent for prolonged release suspension for injection. We worked with manufacturers to uplift production, and the issues were resolved in February 2024. We worked with NHS England to issue national communications containing advice on how to manage patients whilst there was a disruption to supply. We are not aware of any supply issues affecting oral presentations of olanzapine, or of any supply issues with any risperidone or haloperidol products.</p> answering member printed Lord Markham grouped question UIN HL3730 question first answered 22/04/2024 15:15:21 answering member 4948 label Biography information for Lord Markham
	tabling member	1138 label Biography information for Lord Carlile of Berriew

1700672

	registered interest
	date	15/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Olanzapine: Shortages
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what assessment they have made of the impact of the shortage of the psychotropic medication Olanzapine, and what steps they are taking to ensure that such shortages do not affect the health and safety of patients, and wider public safety.
	tabling member printed	Lord Carlile of Berriew
	uin	HL3730
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>We are aware that there have been supply constraints with olanzapine 210 milligram, 300 milligram, and 405 milligram powder and solvent for prolonged release suspension for injection. We worked with manufacturers to uplift production, and the issues were resolved in February 2024. We worked with NHS England to issue national communications containing advice on how to manage patients whilst there was a disruption to supply. We are not aware of any supply issues affecting oral presentations of olanzapine, or of any supply issues with any risperidone or haloperidol products.</p> answering member printed Lord Markham grouped question UIN HL3729 question first answered 22/04/2024 15:15:21 answering member 4948 label Biography information for Lord Markham
	tabling member	1138 label Biography information for Lord Carlile of Berriew

1700674

	registered interest
	date	15/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Tofersen: Licensing
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what assessment they have made of the negative impact on pharmaceutical research investment in the UK of the refusal by National Institute for Health and Care Excellence to approve tofersen for SOD-1 MND patients in the UK.
	tabling member printed	Baroness Finlay of Llandaff
	uin	HL3732
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) has not yet started its evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations, and has therefore not published any guidance or recommendations on whether tofersen should be available for National Health Service patients. In developing its recommendations, the NICE will follow its published methods for health technology evaluation, which will include a thorough assessment of the available evidence. This takes into account all health-related costs and benefits, including health benefits not only to patients but, where relevant, to other people such as carers. The NICE’s aim is to publish its guidance on tofersen as close as possible to the date it receives its marketing authorisation.</p> answering member printed Lord Markham grouped question UIN HL3733 question first answered 22/04/2024 15:05:49 answering member 4948 label Biography information for Lord Markham
	tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1700675

	registered interest
	date	15/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Tofersen
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what consideration was given to the costs of complicated grief in families of patients dying from SOD-1 MND during the evaluation process that led to the decision to decline access to tofersen for NHS patients.
	tabling member printed	Baroness Finlay of Llandaff
	uin	HL3733
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) has not yet started its evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations, and has therefore not published any guidance or recommendations on whether tofersen should be available for National Health Service patients. In developing its recommendations, the NICE will follow its published methods for health technology evaluation, which will include a thorough assessment of the available evidence. This takes into account all health-related costs and benefits, including health benefits not only to patients but, where relevant, to other people such as carers. The NICE’s aim is to publish its guidance on tofersen as close as possible to the date it receives its marketing authorisation.</p> answering member printed Lord Markham grouped question UIN HL3732 question first answered 22/04/2024 15:05:49 answering member 4948 label Biography information for Lord Markham
	tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1700683

	registered interest
	date	15/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Staff
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what is their assessment of the impact of the NHS long-term workforce plan upon the number of specialists such as Parkinson’s nurses in the NHS.
	tabling member printed	Baroness Gale
	uin	HL3741
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>In June 2023, we published the Long Term Workforce Plan which sets out the steps the National Health Service and its partners need to take to deliver an NHS workforce that meets the changing needs of the population over the next 15 years.</p><p>The Plan commits to double the number of medical places, taking the total number of places to 15,000 by 2031/32 and including a commensurate increase in specialty training places that meets the demands of the NHS in the future. It also commits to increasing adult nursing places by 92%, taking the number of total places up to nearly 38,000 by 2031/32.</p><p>There are a record number of nurses working in the NHS and we have reached our target of 50,000 additional nurses, meaning we have delivered on our commitment six months early. In January 2024 there are over 363,000 nurses working across the NHS, representing over 62,000 more than in September 2019.</p> answering member printed Lord Markham question first answered 22/04/2024 15:39:17 answering member 4948 label Biography information for Lord Markham
	tabling member	2503 label Biography information for Baroness Gale

1700742

	registered interest
	date	15/04/2024
	answering body	Department for Environment, Food and Rural Affairs
	answering dept id	13
	answering dept short name	Environment, Food and Rural Affairs
	answering dept sort name	Environment, Food and Rural Affairs
	hansard heading	Hornets
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what assessment they have made of the spread of reported Asian hornet nesting sites in England since 2019.
	tabling member printed	Lord Patten
	uin	HL3781
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>A risk assessment for Asian hornet was completed in 2011. The <a href="https://www.nonnativespecies.org/assets/Uploads/RA_Vespa_velutina_Asian_Hornet.pdf" target="_blank">risk assessment</a> concluded that there were multiple pathways through which Asian hornet could arrive in England and therefore that entry was very likely. Several areas were identified where Asian hornet incursions were thought to be most likely and this included Southern English counties, coastal regions, open areas near fresh water and areas close to ports and airports.</p><p> </p><p>Since 2019 there have been 80 Asian hornet nests located and destroyed in Great Britain with 77 of these nests located in the South of England.</p><p> </p><p>In 2023 there was a large increase in the number of nests when compared to all previous years, with 72 nests located and destroyed. The majority of the nests were located in the South-East (62), while 8 were located in the South and South-West and 2 were located in the North of England.</p><p> </p><p>We ask all members of the public to be vigilant for sightings of Asian hornet during the peak season (June-October) as Asian hornets are known to be an effective hitch hiker and may be spotted anywhere across the country.</p> answering member printed Lord Benyon question first answered 19/04/2024 13:40:59 answering member 1547 label Biography information for Lord Benyon attachment 1 file name HL3781 attachment.pdf title Risk Assessment
	tabling member	1137 label Biography information for Lord Patten

1700743

	registered interest
	date	15/04/2024
	answering body	Department for Environment, Food and Rural Affairs
	answering dept id	13
	answering dept short name	Environment, Food and Rural Affairs
	answering dept sort name	Environment, Food and Rural Affairs
	hansard heading	Hornets
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what assessment they have made of the effect of the spread of Asian hornets on the welfare of (1) honey bees, and (2) other insect populations, in England; and what action they are taking to prevent the further spread of this invasive species.
	tabling member printed	Lord Patten
	uin	HL3782
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>The Government recognises the essential role played by honey bees and wild pollinators in our environment, acknowledging their contribution to crop pollination. Additionally, pollinators play a vital role in supporting the natural ecosystem.</p><p> </p><p>Asian hornets prey on honey bees and other pollinators so pose a significant threat to these insects. To date rapid action has been taken in the UK to find and destroy Asian hornet nests.</p><p> </p><p>In 2023 a total of 72 nests were located and destroyed, the majority of these were located in the South-East (62). The National Bee Unit (NBU), part of the Animal and Plant Health Agency, rapidly located and destroyed the nests so we would expect any impacts on honey bee colonies and other pollinators to be small and localised.</p><p> </p><p>From the analysis of nests found in 2023, a number of areas were identified where there is a low risk that Asian hornet queens may have overwintered. To address this, the NBU is carrying out spring trapping and working collaboratively with stakeholders to monitor traps at locations across Kent, East Sussex, Devon and North Yorkshire.</p><p> </p><p>The Government remains committed to taking swift and effective contingency action against Asian hornet in 2024 thereby continuing to minimise the impacts on honey bees and other pollinators.</p> answering member printed Lord Benyon question first answered 19/04/2024 13:40:12 answering member 1547 label Biography information for Lord Benyon
	tabling member	1137 label Biography information for Lord Patten